Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia

Kidney International

Volumn 75, Issue 1, 2009, Pages 15-24

  Leaf, David E ^a   Goldfarb, David S ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Nephrology Section/111G   (United States)

Author keywords

Chronic kidney disease; Erythropoietin; ESA; Hemodialysis; Hemoglobin; HRQOL

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ANEMIA; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COGNITION; COST EFFECTIVENESS ANALYSIS; EFFECT SIZE; EMOTION; ENERGY; HEMODIALYSIS; HUMAN; MENTAL HEALTH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUALITY; SHORT FORM 36; SICKNESS IMPACT PROFILE; SLEEP; SOCIAL INTERACTION; SYMPTOM; TASK PERFORMANCE; VISUAL ANALOG SCALE;

ANEMIA; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 58049215462     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.414     Document Type: Review

References (71)

1. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
2. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
3. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47: S11-S145.
4. Smith DH, Gullion CM, Nichols G et al. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004; 15: 1300-1306.
5. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-1510.
6. Muzzarelli S, Pfisterer M. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J 2006; 152: 991-996.
7. Kamenetz Y, Beloosesky Y, Zeltzer C et al. Relationship between routine hematological parameters, serum IL-3, IL-6 and erythropoietin and mild anemia and degree of function in the elderly. Aging (Milano) 1998; 10: 32-38.
8. Dharmarajan TS, Norkus EP. Mild anemia and the risk of falls in older adults from nursing homes and the community. J Am Med Dir Assoc 2004; 5: 395-400.
9. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34: 13-19.
10. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-1234.
11. Ross SD, Fahrbach K, Frame D et al. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003; 25: 1786-1805.
12. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD003967. DOI: 10.1002/14651858.CD003967.pub2.
13. Cella DF. Methods and problems in measuring quality of life. Support Care Cancer 1995; 3: 11-22.
14. Coladonato JA, Frankenfield DL, Reddan DN et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002; 13: 1288-1295.
15. Ware Jr JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51: 903-912.
16. Stewart AL, Hays RD, Ware Jr JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724-735.
17. Bergner M, Bobbitt RA, Carter WB et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
18. Baum M, Priestman T, West RR et al. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Eur J Cancer 1980; 16 (Suppl 1): 223-226.
19. Laupacis A, Muirhead N, Keown P et al. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron 1992; 60: 302-306.
20. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395-407.
21. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
22. Samsa G, Edelman D, Rothman ML et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-155.
23. Damiano AM, Steinberg EP, Cassard SD et al. Comparison of generic versus disease-specific measures of functional impairment in patients with cataract. Med Care 1995; 33: AS120-AS130.
24. Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986; 39: 897-906.
25. Todd KH, Funk JP. The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 1996; 3: 142-146.
26. Ander DS, Aisiku IP, Ratcliff JJ et al. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful? Congest Heart Fail 2004; 10: 188-191.
27. Patrick DL, Gagnon DD, Zagari MJ et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39: 335-345.
28. Osoba D, King M. Interpreting QOL in individuals and groups: meaningful differences. In: Fayers P HR (ed). Assessing Quality of Life in Clinical Trials: Methods and Practice, 2nd edn, Oxford University Press, 2005, pp 243-257.
29. Juniper EF, Guyatt GH, Willan A et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81-87.
30. Ehrich EW, Davies GM, Watson DJ et al. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000; 27: 2635-2641.
31. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
32. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-592.
33. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol 1997; 50: 869-879.
34. Ross M. Relation of implicit theories to the construction of personal histories. Psychol Rev 1989; 96: 341-357.
35. Schwartz N, Sudman S. Autobiographical Memory and the Validity of Retrospective Reports. Springer-Verlag: New York, 1994.
36. Cohen J. Statistical Power Analysis for the Behavioural Sciences. Lawrence Earlbaum: New Jersey, 1988.
37. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2: 221-226.
38. Ritz E, Laville M, Bilous RW et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207.
39. Beusterien KM, Nissenson AR, Port FK et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773.
40. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11: 335-342.
41. Moreno F, Aracil F, Perez R et al. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996; 27: 548-556.
42. Deniston OL, Luscombe FA, Buesching DP et al. Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients. ASAIO Trans 1990; 36: M157-M160.
43. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300: 573-578.
44. Provenzano R, Garcia-Mayol L, Suchinda P et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004; 61: 392-405.
45. Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361.
46. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335.
47. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189.
48. Kutner N. Quality of life assessment in a recent haemoglobin trial in CKD (CHOIR). Nephrol Dial Transplant 2007; 22: 2099.
49. McMahon LP, McKenna MJ, Sangkabutra T et al. Physical Performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1182-1187.
50. Mayer G, Thum J, Cada EM et al. Working capacity is increased following treatment with recombinant human erythropoietin. Kidney Int 1988; 34: 525-528.
51. McMahon LP, Johns JA, McKenzie A et al. Haemodynamic changes and physical performance at comparative levels of haemoglobin after longterm treatment with recombinant erythropoietin. Nephrol Dial Transplant 1992; 7: 1199-1206.
52. Barany P, Freyschuss U, Pettersson E et al. Treatment of anaemia in haemodialysis patients with erythropoietin: long term effects on exercise capacity. Clin Sci 1993; 84: 441-447.
53. Lewis NP, Macdougall I, Willis N et al. Effects of the correction of renal anaemia by erythropoietin on physiological changes during exercise. Eur J Clin Invest 1993; 23: 423-427.
54. Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-554.
55. Lefebvre P, Vekeman F, Sarokhan B et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006; 22: 1929-1937.
56. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-895.
57. Shasha D, Cremieux P, Harrison L. Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa. J Natl Compr Cancer Netw 2004; 2: 509-517.
58. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
59. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156.
60. Benz RL, Pressman MR, Hovick ET et al. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999; 34: 1089-1095.
61. Grimm G, Stockenhuber F, Schneeweiss B et al. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990; 38: 480-486.
62. Bowie CR, Harvey PD. Administration and interpretation of the trail making test. Nat Protoc 2006; 1: 2277-2281.
63. Pickett JL, Theberge DC, Brown WS et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999; 33: 1122-1130.
64. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14: 14-18.
65. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990; 263: 825-830.
66. Bottomley A, Thomas R, van Steen K et al. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 2002; 3: 145-153.
67. Kallich J, McDermott A, Xu X et al. The relationship between patient knowledge of hemoglobin levels and health-related quality of life. Qual Life Res 2006; 15: 57-68.
68. Unruh M, Yan G, Radeva M et al. Bias in assessment of health-related quality of life in a hemodialysis population: a comparison of self-administered and interviewer-administered surveys in the HEMO study. J Am Soc Nephrol 2003; 14: 2132-2141.
69. Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs). Administered for the Treatment of Anemia associated with Chronic Renal Failure. In: FDA Advisory Committee Briefing Document: Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee 2007.
70. Trentacosti A. Epoetin Alpha: FDA Overview of Patient Reported Outcome (PRO) Claims. In: www.fda.gov/ohrms/dockets/ac/07/slides/2007-4315s1-09-FDA- Trentacosti.ppt, 2007.
71. Tonelli M, Winkelmayer WC, Jindal KK et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64: 295-304.